{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kinoshita H"],"funding":["NCATS NIH HHS","NHLBI NIH HHS","NCI NIH HHS"],"pagination":["2520-2534"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9043933"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(8)"],"pubmed_abstract":["Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies, with an expected 1-year overall survival (OS) of <20%. We evaluated the safety and clinical outcomes following administration of a novel T-cell therapeutic targeting 3 tumor-associated antigens (TAA-T) in patients with acute leukemia who relapsed or were at high risk of relapse after allogeneic BMT. Lymphocytes obtained from the BMT donor were manufactured to target TAAs WT1, PRAME, and survivin, which are over-expressed and immunogenic in most hematologic malignancies. Patients received TAA-T infusions at doses of 0.5 to 4 × 107/m2. Twenty-three BMT recipients with relapsed/refractory (n = 11) and/or high-risk (n = 12) acute myelo"],"journal":["Blood advances"],"pubmed_title":["Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT."],"pmcid":["PMC9043933"],"funding_grant_id":["P01 CA015396","T32 HL110841","P01 CA225618","UL1 TR001876"],"pubmed_authors":["Jones RJ","Grant M","Dome JS","Zhang N","Lang H","Fortiz MF","Tanna J","Williams KM","Cooke KR","Liang H","Kukadiya D","Zhang A","Shibli A","Dave H","Kinoshita H","Cruz CR","Fulton K","Keller M","Bollard CM","Jacobsohn D","Stanojevic M","Datar A","Barrett AJ","Hoq F","Hanley PJ"],"additional_accession":[]},"is_claimable":false,"name":"Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.","description":"Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies, with an expected 1-year overall survival (OS) of <20%. We evaluated the safety and clinical outcomes following administration of a novel T-cell therapeutic targeting 3 tumor-associated antigens (TAA-T) in patients with acute leukemia who relapsed or were at high risk of relapse after allogeneic BMT. Lymphocytes obtained from the BMT donor were manufactured to target TAAs WT1, PRAME, and survivin, which are over-expressed and immunogenic in most hematologic malignancies. Patients received TAA-T infusions at doses of 0.5 to 4 × 107/m2. Twenty-three BMT recipients with relapsed/refractory (n = 11) and/or high-risk (n = 12) acute myelo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-30T14:48:59.416Z","creation":"2022-07-11T18:36:07.727Z"},"accession":"S-EPMC9043933","cross_references":{"pubmed":["35244681"],"doi":["10.1182/bloodadvances.2021006831"]}}